Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies

被引：2

作者：

Ghobadi, Armin ^{[1
]}

Landmann, Jack H. ^{[1
]}

Carter, Alun ^{[1
]}

Cooper, Matthew L. ^{[1
,3
]}

Selli, Mehmet Emrah ^{[1
]}

Chang, Jufang ^{[1
]}

Baker, Matthew ^{[2
]}

Miller, Christopher A. ^{[1
]}

Ferraro, Francesca ^{[1
]}

Chen, David Y. ^{[1
]}

Smith, Amanda M. ^{[1
]}

LaValle, Taylor A. ^{[1
]}

Duncavage, Eric J. ^{[1
]}

Chou, Justin ^{[4
]}

Tam, Victor ^{[4
]}

Benoun, Joseph M. ^{[4
]}

Nater, Jenny ^{[4
]}

Scholler, Nathalie ^{[4
]}

Milletti, Francesca ^{[4
]}

Vezan, Remus ^{[4
]}

Bot, Adrian ^{[4
]}

Rossi, John M. ^{[4
]}

Singh, Nathan ^{[1
]}

机构：

[1] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA

[2] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA

[3] Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX USA

[4] Kite Gilead Co, Santa Monica, CA USA

来源：

BLOOD ADVANCES | 2022年 / 6卷 / 20期

关键词：

MUTATIONS; CANCER;

D O I：

10.1182/bloodadvances.2022007705

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：5634 / 5640

页数：7

共 50 条

[21] CD19-Targeted CAR T Cells as Novel Cancer Immunotherapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Davila, Marco L.
Brentjens, Renier J.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (10) : 802 - 808
[22] Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells
Cordeiro, Ana
Bezerra, Evandro D.
Hirayama, Alexandre V.
Hill, Joshua A.
Wu, Qian V.
Voutsinas, Jenna
Sorror, Mohamed L.
Turtle, Cameron J.
Maloney, David G.
Bar, Merav
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (01) : 26 - 33
[23] CD19-targeted CAR regulatory T cells suppress B cell pathology without GvHD
Imura, Yuki
Ando, Makoto
Kondo, Taisuke
Ito, Minako
Yoshimura, Akihiko
JCI INSIGHT, 2020, 5 (14)
[24] Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma
Bock, Tamara J.
Colonne, Chanukya K.
Fiorenza, Salvatore
Turtle, Cameron J.
NATURE REVIEWS CLINICAL ONCOLOGY, 2025, : 241 - 261
[25] CD19-Targeted CAR T Cells: A New Tool in the Fight against B Cell Malignancies
Miller, Brian C.
Maus, Marcela V.
ONCOLOGY RESEARCH AND TREATMENT, 2015, 38 (12) : 683 - 690
[26] Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice
Pennell, Christopher A.
Barnum, Jessie L.
McDonald-Hyman, Cameron S.
Panoskaltsis-Mortari, Angela
Riddle, Megan J.
Xiong, Zhengming
Loschi, Michael
Thangavelu, Govindarajan
Campbell, Heather M.
Storlie, Meghan D.
Refaeli, Yosef
Furlan, Scott N.
Jensen, Michael C.
Kean, Leslie S.
Miller, Jeffrey S.
Tolar, Jakub
Osborn, Mark J.
Blazar, Bruce R.
MOLECULAR THERAPY, 2018, 26 (06) : 1423 - 1434
[27] Clinical Immunotherapy of B-Cell Malignancy Using CD19-Targeted CAR T-Cells
Maher, John
CURRENT GENE THERAPY, 2014, 14 (01) : 35 - 43
[28] RE-Treatment with CD19-Targeted CAR-T Cells for Relapse after CD19-CAR-T Cell Therapy
Nishio, Nobuhiro
Hamada, Motoharu
Nishikawa, Eri
Kawashima, Nozomu
Narita, Atsushi
Muramatsu, Hideki
Wang, Kai
Zheng, Huyong
Chang, Jung-Li
Takahashi, Yoshiyuki
PEDIATRIC BLOOD & CANCER, 2021, 68
[29] Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure
Gauthier, Jordan
Hirayama, Alexandre V.
Purushe, Janaki
Hay, Kevin A.
Lymp, James
Li, Daniel H.
Yeung, Cecilia C. S.
Sheih, Alyssa
Pender, Barbara S.
Hawkins, Reed M.
Vakil, Aesha
Tinh-Doan Phi
Steinmetz, Rachel N.
Shadman, Mazyar
Riddell, Stanley R.
Maloney, David G.
Turtle, Cameron J.
BLOOD, 2020, 135 (19) : 1650 - 1660
[30] Unexpected Toxicity of Cyclophosphamide Followed by Adoptively Transferred CD19-Targeted T Cells in a Patient with Bulky CLL
Brentjens, Renier J.
Riviere, Isabelle
Hollyman, Daniel
Taylor, Clare
Nikhamin, Yan
Stefanski, Jolanta
Lee, James
Yeh, Raymond
Santos, Elmer
Sadelain, Michel
MOLECULAR THERAPY, 2009, 17 : S157 - S157

← 1 2 3 4 5 →